ITMCTR2100005445尚未招募1 期
Exploratory Research on the Efficacy Evaluation of Electroacupuncture in the Treatment of Cerebral Apoplexy and Paralysis Stage Based on the Theory of Treating Flaccid Paralysis by Yangming A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 45 至 75（—）
- 性别
- All
入选标准
- •1.For the patients who met the diagnostic criteria for ischemic stroke (with reference to the 2019 edition of Chinese diagnostic criteria for cerebrovascular diseases) and were confirmed as ischemic stroke by CT or MRI, the lesion suggested that the type was hemiplegia due to unilateral hemispheric injury;
- •2.The patient suffers from the first stroke, and the condition is basically stable with no conscious disorder;
- •3.Upper limb Brunnstrom grade 1; Ashworth upper extremity score: 0;
- •4.Vital signs are stable;
- •5.Aged between 45-75 years old; No gender limitation;
- •6.The patient or his/her immediate family members and spouse sign the informed consent form.
排除标准
- •1.There are diseases or conditions that seriously affect patients' activities, such as important organ failure or critical condition, and cancer;
- •2.Patients combined with systemic infection, or the condition is seriously unstable;
- •3.Patients complicated with severe musculoskeletal diseases;
- •4.Patients complicated with severe cognitive and mental diseases;
- •5.Fear of acupuncture and dizziness;
- •6.Patients with heart disease;
- •7.The affected upper limb of the patient has metal implants, and the patient is allergic to EEG ointment;
- •8.Pregnant and lactating women;
- •9.Patients have participated in other clinical trials that affect the evaluation of the results of this study.
研究者
相似试验
招募中
1 期
Clinical Trial for Prevention of Cisplatin-Induced Renal NephrotoxicityCancerJPRN-jRCTs041220021Kondo Masashi21
招募中
Unknown
Exploratory study of CLZ-BM3D in patients with peripheral occlusive arterial diseasePatients with peripheral occlusive arterial diseaseJPRN-jRCT2072220114akamura Masato24
进行中（未招募）
1 期
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.Chronic spontaneous urticaria and the following skin disorders:1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermatitis, dyshidrotic eczema, asteatotic eczema, lichen simplex chronicus).2 - Prurigo (acute prurigo, subacute prurigo, chronic prurigo).3 - Cutaneous pruritus (systemic cutaneous pruritus, local cutaneous pruritus).MedDRA version: 19.0Level: HLTClassification code 10012435Term: Dermatitis and eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10037083Term: PrurigoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-001505-17-ESFAES FARMA, S.A.115
进行中（未招募）
1 期
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.EUCTR2016-001505-17-HUFAES FARMA, S.A.115
进行中（未招募）
1 期
The exploratory study of EFE in COVID-19 patientsCOVID-19JPRN-jRCT2031210063Odaguchi Hiroshi156